StemoniX

StemoniX is a biotech startup that develop and scalably manufactures human induced pluripotent stem (iPS) cell-derived cardiac and neural platforms for drug discovery and development. Predictive, accurate, and consistent, our human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow.

StemoniX provides products and services for drug discovery and development. We structure human iPSC-derived cells into physiologically relevant microtissues with accelerated cell maturity that mimic the native organ tissue. Predictive, accurate, and consistent, our in vitro human cell-based products enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow.

StemoniX was founded in 2014 by Ping Yeh & Bob Petcavich and is based in Minneapolis, Minnesota with an additional office in LA Jolla, California.

StemoniX's solution enables scaled 3-D printing of living cells into larger form factors for heart disease, dementia, breast cancer, autism, ALS, and more. 

StemoniX offers StemoniX, a platform that focuses on printing of stem-cell derived human tissue for custom drug discovery and personalized medicine. It seeks to transform conventional drug development via iPSC-derived, ready-to-use assay plates containing functional microOrgans®, including synapsing brain cells (microBrain®) and beating heart cells (microHeart®).

 

StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity. StemoniX microBrain® products in high density formats are physiologically relevant with biology, activity, functional maturity that mimic native human brain tissue.

 

StemoniX is backed by Brightstone Venture Capital, Mayo Clinic, Keshif Ventures, & Alumni Ventures Group among others.

 

StemoniX has received multiple awards and accolades which including, 2018 Edison Award Gold, 2018 Most Innovative New Product Awards Winner, 2018 Tekne Awards Finalist, 2017 Red Herring Top 100 North America award for revolutionizing the way medicine is discovered. And was recognized as one of North America's most exciting and innovative tech companies.

 

 

  • Year founded: 2014
  • Funding Info: $26.1M in 6 Funding Rounds (Last Funding Type: Series B)
  • Yearly Revenue: $5M-$10M (2018)
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Minneapolis
  • State: Minnesota
  • Country: United States
Related businesses